Cargando…

Effects of ezetimibe add-on therapy for high-risk patients with dyslipidemia

BACKGROUND: Ezetimibe (Zetia(®)) is a potent inhibitor of cholesterol absorption that has been approved for the treatment of hypercholesterolemia. Statin, an inhibitor of cholesterol synthesis, is the first-choice drug to reduce low-density lipoprotein-cholesterol (LDL-C) for patients with hyperchol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamaoka-Tojo, Minako, Tojo, Taiki, Kosugi, Rie, Hatakeyama, Yuko, Yoshida, Yuki, Machida, Yoji, Aoyama, Naoyoshi, Masuda, Takashi, Izumi, Tohru
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768708/ https://www.ncbi.nlm.nih.gov/pubmed/19821987 http://dx.doi.org/10.1186/1476-511X-8-41

Ejemplares similares

Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease
por: Yamaoka-Tojo, Minako, et al.
Publicado: (2010)

Circulating interleukin-18: A specific biomarker for atherosclerosis-prone patients with metabolic syndrome
por: Yamaoka-Tojo, Minako, et al.
Publicado: (2011)

Postprandial hyperglycemia and endothelial function in type 2 diabetes: focus on mitiglinide
por: Kitasato, Lisa, et al.
Publicado: (2012)

Molecular Mechanisms Underlying the Progression of Aortic Valve Stenosis: Bioinformatic Analysis of Signal Pathways and Hub Genes
por: Tojo, Taiki, et al.
Publicado: (2023)

Long-term warfarin therapy and biomarkers for osteoporosis and atherosclerosis
por: Namba, Sayaka, et al.
Publicado: (2015)

Combination Therapy of Ezetimibe and Rosuvastatin for Dyslipidemia: Current Insights
por: Chilbert, Maya R, et al.
Publicado: (2022)

Endothelial glycocalyx damage as a systemic inflammatory microvascular endotheliopathy in COVID-19
por: Yamaoka-Tojo, Minako
Publicado: (2020)

Vascular Endothelial Glycocalyx Damage in COVID-19
por: Yamaoka-Tojo, Minako
Publicado: (2020)

Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia
por: Lee, Jeongmin, et al.
Publicado: (2023)

Ezetimibe Monotherapy Reduces Serum Levels of Platelet-Activating Factor Acetylhydrolase in Patients With Dyslipidemia
por: Tano, Kanako, et al.
Publicado: (2019)

Treatment of dyslipidemia with lovastatin and ezetimibe in an adolescent with cholesterol ester storage disease
por: Tadiboyina, Venu T, et al.
Publicado: (2005)

Effect of cardiac rehabilitation on cognitive function in elderly patients with cardiovascular diseases
por: Fujiyoshi, Kazuhiro, et al.
Publicado: (2020)

Advanced Glycation End Products Are Associated with Diabetes Status and Physical Functions in Patients with Cardiovascular Disease
por: Hirai, Tomoya, et al.
Publicado: (2022)

Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia
por: Kumar, Shoba Sujana, et al.
Publicado: (2009)

The Efficacy and Safety of Ezetimibe and Low-Dose Simvastatin as a Primary Treatment for Dyslipidemia in Renal Transplant Recipients
por: Yoon, Hye Eun, et al.
Publicado: (2009)

Dyslipidemia in HIV-positive patients: a randomized, controlled, prospective study on ezetimibe+fenofibrate versus pravastatin monotherapy
por: Grandi, Anna M, et al.
Publicado: (2014)

Effects of pitavastatin add-on therapy on chronic kidney disease with albuminuria and dyslipidemia
por: Ohsawa, Masato, et al.
Publicado: (2015)

Safety and efficacy of long-term combination therapy with bezafibrate and ezetimibe in patients with dyslipidemia in the prospective, observational J-COMPATIBLE study
por: Teramoto, Tamio, et al.
Publicado: (2013)

Efficacy and Tolerability of a Fixed-Dose Combination of Rosuvastatin and Ezetimibe Compared with a Fixed-Dose Combination of Simvastatin and Ezetimibe in Brazilian Patients with Primary Hypercholesterolemia or Mixed Dyslipidemia: A Multicenter, Randomized Trial
por: Vattimo, Antonio Carlos Amedeo, et al.
Publicado: (2020)

Lower Level of Low Density Lipoprotein Cholesterol is Associated with a Higher Increase in the Fractional Flow Reserve in Patients with Fixed-dose Rosuvastatin
por: Hashikata, Takehiro, et al.
Publicado: (2018)

Effects of ezetimibe on cholesterol metabolism in HIV-infected patients with protease inhibitor-associated dyslipidemia: a single-arm intervention trial
por: Leyes, Pere, et al.
Publicado: (2014)

Fungal biotransformation of ezetimibe
por: Pervaiz, Irfan, et al.
Publicado: (2014)

Real-World Evidence Evaluation on the Lipid Profile, Therapeutic Goals, and Safety of the Fixed-Dose Combination of Rosuvastatin/Ezetimibe (Trezete®) in Dyslipidemia Patients
por: Rodríguez-Saldaña, Joel, et al.
Publicado: (2022)

Effect of ezetimibe add-on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects
por: Sakamoto, Kentaro, et al.
Publicado: (2017)

Clinical and Microbiological Features of Asymptomatic SARS-CoV-2 Infection and Mild COVID-19 in Seven Crewmembers of a Cruise Ship
por: Hoshiyama, Takayuki, et al.
Publicado: (2020)

Ezetimibe: An Unusual Suspect in Angioedema
por: Lu, Tiffany, et al.
Publicado: (2020)

Synthesis and Modeling of Ezetimibe Analogues
por: Salgado, Mateo M., et al.
Publicado: (2021)

Ezetimibe and Cancer: Is There a Connection?
por: Gu, Jia, et al.
Publicado: (2022)

Efficacy of Ezetimibe/Simvastatin (10/10 mg) versus High Dose Statin in Dyslipidemia Patients: A Meta-Analysis of Randomized Controlled Trials
por: YANG, Gaoming, et al.
Publicado: (2019)

A comparison of the effects of monotherapy with rosuvastatin, atorvastatin or ezetimibe versus combination treatment with rosuvastatin-ezetimibe and atorvastatin-ezetimibe on the integrity of vascular endothelial cells damaged by oxidized cholesterol
por: Niedzielski, Mateusz, et al.
Publicado: (2021)

Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study
por: Zhu, Lin, et al.
Publicado: (2020)

Ezetimibe, cardiovascular risk and atherogenic dyslipidaemia
por: Rizzo, Manfredi, et al.
Publicado: (2011)

Liver Injury Associated With Ezetimibe Monotherapy
por: Kanagalingam, Tharsan, et al.
Publicado: (2020)

Ezetimibe reduced hepatic steatosis induced by dietary oxysterols in nonhuman primates
por: Deushi, Michiyo, et al.
Publicado: (2016)

Distinctive Gut Microbiota in Patients with Overweight and Obesity with Dyslipidemia and its Responses to Long-term Orlistat and Ezetimibe Intervention: A Randomized Controlled Open-label Trial
por: Jin, Jin, et al.
Publicado: (2021)

Ezetimibe therapy: mechanism of action and clinical update
por: Phan, Binh An P, et al.
Publicado: (2012)

Ezetimibe: Clinical and Scientific Meaning of the IMPROVE-IT Study
por: Correia, Luis C. L.
Publicado: (2016)

Impact on urinary oxalate levels with use of ezetimibe
por: Trautman, Christopher L., et al.
Publicado: (2021)

IMPROVE-IT: A Final Closure to Carcinogenicity of Ezetimibe?
por: Lewis, Eldrin F., et al.
Publicado: (2020)

Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin
por: Farnier, Michel, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_0m60io3n4h8kqt02e71cpg5voh